Navigation Links
Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA
Date:4/28/2009

DALLAS, April 28 /PRNewswire/ -- BeaconEquity.com announces the availability of Stock Alerts on stocks making news today. As the influenza dominates the headlines, several biopharmaceutical stocks are parading up the charts.

So how does swine flu affect the markets? Check out a video chart for three stocks (BCRX, AVII, DVAX) reeling from influenza news that should be on your radar this week at stockhideout.com.

Today's Stock Alerts include: Hemispherx Biopharma Inc. (AMEX: HEB), Generex Biotechnology Corp. (Nasdaq: GNBT), BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX), Dynavax Technologies Corp. (Nasdaq: DVAX), Novavax Inc. (Nasdaq: NVAX) and Sinovac Biotech Ltd. (AMEX: SVA).

Investors can view all of the daily stock alerts for free by visiting BeaconEquity.com/m.

See what Cramer has to say about these stocks and many more.

BeaconEquity.com's Stock Alerts are brief analyses on the active stocks each day that are affecting the markets. These include breaking news, insider activity, recent 52-week highs/lows, technical breakouts, and other market driving information. Beacon is the authority on research in the small-cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.

We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.

BeaconEquity.com is one of the industry's largest small-cap research providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit:

http://www.BeaconEquity.com/m CRD# 2207572

BeaconEquity.com Disclosure

BeaconEquity.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BeaconEquity.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, BeaconEquity.com, for complete risks and disclosures.

David C. Masson of Beacon Equity Research is a member of the National Association of Securities Dealers, CRD number 2207572.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

JEFF BISHOP

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=70781

         Beacon Equity Research
         Jeff Bishop, (469)-252-3505
         press@beaconequity.com


'/>"/>
SOURCE BeaconEquity.com
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
2. Companys Partner Completes Trial Production of a New Antiviral Medicine
3. Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray
4. INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
7. Neuralstem Shares Accepted for Trading on Amex(R)
8. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
9. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
10. Essilor Cancels 700,000 Shares
11. Helix BioPharma announces $16.9 million private placement of common shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):